Literature DB >> 30894379

Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.

Fatima Ahmetlić1,2, Tanja Riedel2, Nadine Hömberg1,2, Vera Bauer1, Nico Trautwein3, Albert Geishauser1,2, Tim Sparwasser4, Stefan Stevanović3, Martin Röcken5, Ralph Mocikat6,2.   

Abstract

Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antigenic specificities of tumor-infiltrating Tregs. We addressed this question by using a λ-MYC transgenic mouse model of endogenously arising B-cell lymphoma, which mirrors key features of human Burkitt lymphoma. We show that Foxp3+ Tregs suppress antitumor responses in endogenous lymphoma. Ablation of Foxp3+ Tregs significantly delayed tumor development. The ratio of Treg to effector T cells was elevated in growing tumors, which could be ascribed to differential proliferation. The Tregs detected were mainly natural Tregs that apparently recognized self-antigens. We identified MHC class II-restricted nonmutated self-epitopes, which were more prevalent in lymphoma than in normal B cells and could be recognized by Tregs. These epitopes were derived from proteins that are associated with cellular processes related to malignancy and may be overexpressed in the tumor. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30894379     DOI: 10.1158/2326-6066.CIR-18-0419

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  6 in total

1.  Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1-Resistant Melanoma.

Authors:  Karla M Viramontes; Emily N Neubert; Julia M DeRogatis; Monique L Henriquez; Christian F Guerrero-Juarez; Roberto Tinoco
Journal:  Cancer Immunol Res       Date:  2022-05-03       Impact factor: 12.020

Review 2.  Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors:  Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal:  Bioact Mater       Date:  2021-03-18

3.  Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment.

Authors:  Hao Wang; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Juan Deng; Caicun Zhou; Yayi He
Journal:  Onco Targets Ther       Date:  2019-09-05       Impact factor: 4.147

4.  Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours.

Authors:  Ellen Brenner; Barbara F Schörg; Fatima Ahmetlić; Thomas Wieder; Franz Joachim Hilke; Nadine Simon; Christopher Schroeder; German Demidov; Tanja Riedel; Birgit Fehrenbacher; Martin Schaller; Andrea Forschner; Thomas Eigentler; Heike Niessner; Tobias Sinnberg; Katharina S Böhm; Nadine Hömberg; Heidi Braumüller; Daniel Dauch; Stefan Zwirner; Lars Zender; Dominik Sonanini; Albert Geishauser; Jürgen Bauer; Martin Eichner; Katja J Jarick; Andreas Beilhack; Saskia Biskup; Dennis Döcker; Dirk Schadendorf; Leticia Quintanilla-Martinez; Bernd J Pichler; Manfred Kneilling; Ralph Mocikat; Martin Röcken
Journal:  Nat Commun       Date:  2020-03-12       Impact factor: 14.919

Review 5.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects.

Authors:  Chunxiao Li; Ping Jiang; Shuhua Wei; Xiaofei Xu; Junjie Wang
Journal:  Mol Cancer       Date:  2020-07-17       Impact factor: 27.401

Review 6.  Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.

Authors:  Kamira Maharaj; Angimar Uriepero; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Front Immunol       Date:  2022-08-01       Impact factor: 8.786

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.